(Q30375972)

21 June 2017

1 reference

title

Progress with human H5N1 vaccines: a perspective from industry. (English)

1 reference

21 June 2017

Bram Palache

1

1 reference

21 June 2017

Ryoko Krause

series ordinal

2

1 reference

21 June 2017

publication date

1 April 2009

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

391-400

1 reference

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

21 June 2017

cites work

1 reference

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

The macro-epidemiology of influenza vaccination in 56 countries, 1997--2003.

21 January 2018

1 reference

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

Mitigation strategies for pandemic influenza in the United States.

21 January 2018

1 reference

Strategies for mitigating an influenza pandemic

21 January 2018

1 reference

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.16

1 reference

21 June 2017

1 reference